TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28822007
Drug: 4 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 cycles concurrent epirubicin and cyclophosphamide followed by 10 cycles of weekly paclitaxel combined with 4 cycles capecitabine (EC-TX)
Study: 28822007
Drug: ETC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETC treatment
Study: 24227635
Drug: Sertraline 50mg
Normalized name: sertraline 50 MG
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline 50mg
Study: 22558108
Drug: Ready-to-use therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ready-to-use therapeutic food (RUTF) - daily supplemental RUTF (high-protein peanut-based paste) for 14 days
Study: 11442499
Drug: Clodronate (1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate (1600 mg/d)
Study: 2150785
Drug: Single administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single administration of 250 mg of caffeine (a)
Study: 2150785
Drug: Continuous administration
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous administration of 250 mg caffeine per day for 5 days (c)
Study: 25134312
Drug: Moisturising leave‐on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moisturising leave‐on lotion (LOL) containing 10% glycerol, applied 3 times per week for 8 weeks.
Study: 12637480
Drug: Intravenous irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous irinotecan plus oral ciclosporin
Study: 12730797
Drug: SR 1
Normalized name: SR 140333
DrugBank: SR 140333 (DB05790)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR 1 g/day
Study: 12730797
Drug: SR 2
Normalized name: Calan SR 240mg Extended-Release Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR 2 g/day
Study: 12730797
Drug: SR (higher-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR (higher-dose group)
Study: 8675080
Drug: Cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (10 mg four times daily orally)
Study: 1736933
Drug: Chlorthalidone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (25 mg/daily) with weight loss
Study: 1736933
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 mg/daily) with weight loss
Study: 1736933
Drug: Sodium restriction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium restriction (reduced sodium to less than 70 mEq daily)
Study: 6228913
Drug: Aspirin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (1 g) + Dipyridamole (225 mg)
Study: 26407603
Drug: ABT-436 100
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-436 100 mg
Study: 26407603
Drug: ABT-436 500
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-436 500 mg
Study: 26407603
Drug: ABT-436 800
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-436 800 mg
Study: 26407603
Drug: ABT-436 200
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-436 200 mg (morning regimen)
Study: 26407603
Drug: ABT-436 200
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-436 200 mg (evening regimen)
Study: 20152042
Drug: Glucosamine sulphate
Normalized name: Glucosamine Sulfate 750 MG Oral Capsule [GLUCOSAMINE SULPHATE]
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine sulphate (1500 mg per day for 6 weeks) followed by a 12-week progressive walking program (3000 to 6000 steps/day)
Study: 11177189
Drug: Low fat
Normalized name: Low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fat content breakfast (L)
Study: 6203288
Drug: Naloxone hydrochloride
Normalized name: Naloxone Hydrochloride
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naloxone hydrochloride (opiate antagonist)
Study: 23426563
Drug: Kinesio taping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinesio taping treatment for gastrocnemius muscle enhancement and ankle functional correction
Study: 20664017
Drug: Electronic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electronic insulin order template
Study: 20664017
Drug: Usual insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual insulin ordering
Study: 18246990
Drug: Coffee (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coffee (200 mg of caffeine)
Study: 18246990
Drug: Placebo (decaffeinated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (decaffeinated coffee, 15 mg of caffeine)
Study: 11515632
Drug: Flumazenil 2
Normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flumazenil 2 mg iv (group A)
Study: 29264937
Drug: PCT-guided antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCT-guided antibiotic treatment
Study: 26220089
Drug: Psychodynamic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychodynamic group therapy
Study: 21427564
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 1.5 mg/kg body weight/d
Study: 14655198
Drug: Ciprofloxacin 750
Normalized name: ciprofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 750 mg plus 7 sevelamer hydrochloride 403 mg capsules (Arm B)
Study: 14655198
Drug: Ciprofloxacin 750
Normalized name: ciprofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 750 mg plus 4 calcium acetate 667 mg tablets (Arm C)
Study: 14655198
Drug: Ciprofloxacin 750
Normalized name: ciprofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 750 mg alone (Arm A)
Study: 9262430
Drug: Coca chewing
Normalized name: ERYTHROXYLUM COCA LEAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coca chewing (15 g of coca leaves)
Study: 27105047
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg/day (moderate intensity)
Study: 27105047
Drug: Atorvastatin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 60 mg/day (high intensity)
Study: 10910027
Drug: Prednisolone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (mean dose 38 mg/day)
Study: 8843769
Drug: Intravenous loxiglumide
Normalized name: Dexloxiglumide
DrugBank: Dexloxiglumide (DB04856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous loxiglumide
Study: 3258993
Drug: co-trimoxazole (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: co-trimoxazole (160 mg trimethoprim plus 800 mg sulphamethoxazole) every 12 hours for 15 days
Study: 3258993
Drug: cephalexin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: cephalexin (500 mg) every 6 hours for 15 days
Study: 29857271
Drug: DAPT (clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPT (clopidogrel + aspirin)
Study: 27261980
Drug: Foot-bathing therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foot-bathing therapy at 40°C for 30 minutes daily for four weeks
Study: 27261980
Drug: Foot-bathing therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foot-bathing therapy at 36.5°C for 30 minutes daily for four weeks (placebo)
Study: 21057977
Drug: Ciprofloxacin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (250 or 500 mg twice daily)
Study: 20084975
Drug: Groups A
Normalized name: Meningococcal Polysaccharide Vaccine, Groups A, C Combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Groups A and C conjugate Vaccine with MenB‐OMP
Study: 20084975
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (other vaccine)
Study: 17454586
Drug: Chemotherapy (e.g.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (e.g. melphalan, thalidomide)
Study: 17454586
Drug: High-dose treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose treatment with stem-cell support (autologous and allogeneic)
Study: 31685285
Drug: TAU +
Normalized name: Interferon tau
DrugBank: Interferon tau (DB16972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU + AE (treatment as usual + aerobic exercises)
Study: 26293657
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy group intervention (n=9)
Study: 12871871
Drug: Metformin (2.55
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2.55 g/day) for 12 months
Study: 12871871
Drug: Pioglitazone (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (45 mg/day) + Metformin diet for 10 months
Study: 12871871
Drug: Metformin diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin diet for 26 responders (N=26)
Study: 10965008
Drug: Spinal cord
Normalized name: BOS TAURUS SPINAL CORD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal cord stimulation plus physical therapy
Study: 7233297
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 (PGE) 4 mg administered as an intrarectal suppository
Study: 7233297
Drug: Intravaginally administered
Normalized name: Intravaginal contraceptives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginally administered PGE
Study: 29116326
Drug: Single-Radius (SR)
Normalized name: radium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-Radius (SR) implant
Study: 29116326
Drug: Multi-Radius (J-Curve,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-Radius (J-Curve, JC) implant
Study: 1537636
Drug: Family therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family therapy intervention
Study: 20501479
Drug: Perindopril-indapamide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril-indapamide (4 mg/1.25 mg)
Study: 15735183
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily injection (MDI) therapy with insulin aspart and insulin glargine
Study: 8522408
Drug: Captopril 6.25
Normalized name: captopril 6.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 6.25 mg orally 15 min before thrombolysis
Study: 28043754
Drug: High medication
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High medication adherence
Study: 24976394
Drug: Quetiapine (to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (to 600 mg/d)
Study: 22950430
Drug: Estrogen replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen replacement therapy with 1 mg of estradiol hemihydrate (1 mg/day) orally for 6 months
Study: 18719013
Drug: Combined hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined hormone replacement therapy (HRT) - Conjugated equine oestrogen 0.625 mg plus medroxyprogesterone acetate 2.5/5.0 mg orally daily for one year
Study: 15955017
Drug: Reimbursement for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reimbursement for nicotine replacement therapy, bupropion and behavioural counselling (intervention group)
Study: 10352773
Drug: Dilute epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dilute epinephrine saline irrigation (1 mg/l)
Study: 23009302
Drug: Managed controlled-opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Managed controlled-opioid prescription monitoring program
Study: 18175829
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol 400 microg
Study: 11230838
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg/day (n = 730)
Study: 11230838
Drug: Simvastatin 10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 10 mg/day (n = 694)
Study: 8067763
Drug: Foscarnet (maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foscarnet (maintenance therapy)
Study: 28126707
Drug: Nurses' recommendations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurses' recommendations to intensify treatment
Study: 28126707
Drug: Recommendations to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommendations to start treatment
Study: 28126707
Drug: Renal providers'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal providers' willingness to provide treatment
Study: 26218871
Drug: Osmotic Release
Normalized name: nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Osmotic Release Oral System-Methylphenidate (OROS-MPH)
Study: 10555127
Drug: Topotecan (dl-5)
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topotecan (dl-5) and cytarabine (1 g/m2 over 2 hours; dl-5)
Study: 10555127
Drug: Topotecan (d1-5)
Normalized name: PHOSPHOLIPASE D1
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topotecan (d1-5) followed by etoposide (250 mg/m2 twice daily, d6-7)
Study: 10555127
Drug: Etoposide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide (250 mg/m2 twice daily dl-2) followed by topotecan (d3-d7)
Study: 8670317
Drug: anti-CD5 ricin-linked
Normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-CD5 ricin-linked immunoconjugate (CD5-IC) at doses up to 8 mg/m2/day for 4 days in 1 month
Study: 19910627
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (2.5 mg)
Study: 11094007
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine and clonidine combination
Study: 11094007
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine alone
Study: 8880835
Drug: Opioid antagonist
Normalized name: OPIOID ANTAGONIST ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid antagonist naltrexone (low dose)
Study: 8880835
Drug: Opioid antagonist
Normalized name: OPIOID ANTAGONIST ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid antagonist naltrexone (high dose)
Study: 19955827
Drug: Nebivolol added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol added to antihypertensive treatment
Study: 18818173
Drug: Intervention Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention Group (n=100) - integrated intervention program including diabetes education, frequent blood glucose monitoring, nutritional counseling, meal plans with diabetes-specific nutritional meal replacement, and weekly progress updates
Study: 12444889
Drug: ATD combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATD combined with l‐thyroxine (l‐T(4))
Study: 12444889
Drug: TRAb positive
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRAb positive after 12 Months of antithyroid therapy
Study: 7584765
Drug: Dextromethorphan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan (40 mg)
Study: 7584765
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 mL sucrose)
Study: 1901280
Drug: hMG therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: hMG therapy (alone or in combination with clomiphene citrate or gonadotropin‐releasing hormone agonist analog)
Study: 1901280
Drug: hMG therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: hMG therapy in oligomenorrhea and PCOD patients
Study: 1901280
Drug: hMG therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: hMG therapy in hypogonadotropic amenorrhea patients
Study: 6129142
Drug: Prenalterol (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenalterol (i.v. doses)
Study: 6129142
Drug: Saline (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (i.v. doses)
Study: 6129142
Drug: Prenalterol (inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenalterol (inhaled doses)
Study: 6129142
Drug: Saline (inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (inhaled doses)
Study: 6129142
Drug: Terbutaline (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (i.v. doses after prenalterol/saline)
Study: 6129142
Drug: Prenalterol (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenalterol (i.v. and inhaled doses)
Study: 28598231
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of ursolic acid once a day for 12 weeks
Study: 25579091
Drug: AK106‐001616 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK106‐001616 200 mg
Study: 25579091
Drug: AK106‐001616 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK106‐001616 400 mg
Study: 25579091
Drug: AK106‐001616 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK106‐001616 600 mg
Study: 21504953
Drug: Thermal stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermal stimulation therapy (standard rehabilitation plus approximately 30-40 minutes of thermal stimulation daily for six weeks)
Study: 19644227
Drug: Reboxetine (2-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine (2-8 mg/d)
Study: 19644227
Drug: Methylphenidate (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (10-20 mg/d)
Study: 9135360
Drug: midazolam 0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: midazolam 0.025 mg kg‐1 i.m.
Study: 9135360
Drug: midazolam 0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: midazolam 0.075 mg kg‐1 i.m.
Study: 9135360
Drug: control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: control (no midazolam administration)
Study: 24239324
Drug: 0.75 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg/kg primaquine
Study: 24239324
Drug: 0.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/kg primaquine
Study: 24239324
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg primaquine
Study: 23107470
Drug: Conventional Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Western medicine and Bu‐Fei Jian‐Pi granules, Bu‐Fei Yi‐Shen granules, and Yi‐Qi Zi‐Shen granules
Study: 18400400
Drug: Pregabalin (optimal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (optimal fixed dosages of 300, 450, 600 mg/d)
Study: 12583552
Drug: 5-day treatment
Normalized name: 30 day Acne Treatment Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day treatment course with oral moxifloxacin (MXF)
Study: 9640223
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (rhEPO) at a dose of 150 U/kg/dose subcutaneously three times/week for a minimum of 12 weeks
Study: 2530318
Drug: Circadian patterned
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circadian patterned variable rate infusion of floxuridine (FUDR)
Study: 2530318
Drug: Constant rate
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant rate infusion of floxuridine (FUDR)
Study: 2530318
Drug: Time-modified FUDR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-modified FUDR infusion
Study: 2530318
Drug: FUDR infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: FUDR infusion
Study: 28343659
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg zinc oxide (n=144)
Study: 28343659
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg ferrous fumarate (n=148)
Study: 21689865
Drug: Aerosolized buccal
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosolized buccal midazolam
Study: 21689865
Drug: Aerosolized intranasal
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized intranasal midazolam
Study: 16483431
Drug: Subcutaneous infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous infiltration of metronidazole (group B)
Study: 12603860
Drug: Topical glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical glucocorticoid (clobetasol), applied for 3 days
Study: 12603860
Drug: Topical applications
Normalized name: honey based topical applications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical applications of an equimolar distribution of free fatty acids, cholesterol, and ceramides
Study: 8165610
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (adapted doses, continuous intravenous)
Study: 8165610
Drug: Enoxaparin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (1 mg/kg every twelve hours, subcutaneously)
Study: 11697840
Drug: Weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly docetaxel 36 mg/m2 i.v. administered weekly for six consecutive weeks followed by two weeks without treatment
Study: 8151485
Drug: Lidocaine-prilocaine 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine-prilocaine 5% cream (EMLA)
Study: 3143625
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition and nil by mouth (n = 17)
Study: 3143625
Drug: Defined formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defined formula diet administered through a nasogastric tube (n = 19)
Study: 3143625
Drug: Partial parenteral
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial parenteral nutrition and oral food (n = 15)
Study: 28892156
Drug: Polydextrose (PDX)
Normalized name: Polydextrose
DrugBank: Polydextrose (DB14836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polydextrose (PDX) in beverage at 0, 8, 12, and 16 g
Study: 28892156
Drug: Polydextrose (PDX)
Normalized name: Polydextrose
DrugBank: Polydextrose (DB14836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polydextrose (PDX) in bar at 0 and 12 g
Study: 23017510
Drug: Saw palmetto
Normalized name: Saw palmetto
DrugBank: Saw palmetto (DB14360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saw palmetto treatment
Study: 16586079
Drug: Preserved flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preserved flow with decreased glucose metabolism
Study: 16586079
Drug: Decreased flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decreased flow with preserved glucose metabolism
Study: 10970684
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with SRL172 (Mycobacterium vaccae)